SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca is seeing significant buying momentum as community members discuss its potential for a short squeeze and long-term utility within the Solana DeFi ecosystem. Traders are actively debating entry points and price targets while highlighting the platform's role as a key decentralized exchange for Solana.

Maulcoin

Maulcoin is trending as investors debate its long-term viability, with the community actively split between supporters pushing for growth around upcoming May 4th milestones and critics labeling the project a potential rug pull. Sentiment remains highly polarized, driven by ongoing internal tensions and aggressive cross-platform promotion efforts.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and social media users react to a high-profile security incident involving an evacuation at the White House Correspondents' Dinner, fueling intense community debate regarding the event's authenticity and political motives. Conversations are heavily polarized, with users analyzing potential market impacts on the stock while debating the broader context of the administration's political challenges and the ongoing scrutiny surrounding the company's leadership.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is currently a focal point for investors due to positive clinical data for its lead oncology programs, alongside ongoing institutional accumulation and anticipation of near-term catalyst readouts. The community is actively debating the company's valuation, pipeline depth in synthetic lethality, and the potential for a strategic M&A event given its highly proprietary platform.

KAT is a defi token with governance-like mechanics for Katana.  It is designed to function as a lever for directing capital: users that lock KAT receive a voting version of KAT — vKAT — in return. vKAT underpins key aspects of the chain’s economy, providing rewards to those users that participate. these fee-based rewards function as an incentive for KAT holders to engage in cooperative, positive-sum behavior.

Katana

Katana is gaining significant market attention as traders react to new tokenomics integrations and speculation regarding potential migration plans, fueling intense community debate between bullish growth projections and concerns over volatility. The asset remains a focal point for active trading communities discussing high volume, recent price consolidation, and the impact of its ecosystem's expansion on long-term utility.

Dave, Inc. is a digital banking service. Its products include a budgeting tool to help members manage their upcoming bills to avoid overspending, cash advances through its flagship ExtraCash product to help members avoid punitive overdraft fees, a Side Hustle product, where Dave helps connect members with supplemental work opportunities, and Dave Banking, a modern checking account experience with valuable tools for building long-term financial health. The company was founded by Jason Wilk, Paras Chitrakar, and John Wolanin in October 2015 and is headquartered in Los Angeles, CA.

Dave Inc - Ordinary Shares - Class A

Dave Inc. is trending as traders closely monitor its technical breakout potential and strong Q3 performance, with the community highlighting its high operating leverage and the disruptive potential of its AI-powered underwriting platform. Investors remain focused on the company's path to profitability and its strategic positioning in the neobanking sector, often drawing comparisons to other high-growth fintech peers.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is currently facing significant volatility following a convertible notes offering and insider share sales, leaving the community divided between long-term confidence in its gene-editing pipeline and frustration over the company's management and share performance. Traders are closely monitoring upcoming clinical data readouts and potential acquisition interest while debating whether the current price represents a generational buying opportunity or ongoing stagnation.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The biotech sector is experiencing high investor interest driven by a wave of strategic M&A activity and positive clinical guideline updates, such as NCCN's expanded recommendations for oncology therapies. Investors are actively discussing the potential for structural squeezes in heavily shorted tickers and monitoring the interplay between biotech's clinical momentum and broader market macro volatility.

Index Coop is a decentralized autonomous organization (DAO) that builds structured DeFi products and strategy tokens. Index Coop offers a suite of sector index products, leverage and inverse products, and yield-generating products. The product suite runs on Set Protocol, an audited, self-custodial DeFi tool that allows for the creation and management of Ethereum-based (or ERC-20) tokens. Changes to the DAO are voted on by the owners of a governance token called INDEX and then implemented by a team of developers. INDEX holders wield voting power on a 1:1 basis, meaning one token equals one vote.

Index Cooperative

Index Cooperative is trending as community members speculate on its low circulating supply and potential for volatility, drawing comparisons to other small-cap assets. The conversation is dominated by users betting on a breakout while actively coordinating to drive interest and volume.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently facing intense community debate as it hovers near key resistance levels, with investors torn between bullish sentiment driven by institutional ETF inflows and bearish fears regarding potential supply-side volatility and geopolitical uncertainty. Social discourse is heavily divided between those anticipating a major breakout toward new highs and others cautioning that the asset may be due for a sharp correction as it attempts to decouple from broader macroeconomic pressures.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Adicet Bio, Inc. (NASDAQ:ACET) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold ra...

Adicet Bio (NASDAQ:ACET) Stock Passes Below Two Hundred Day Moving Average - Here's Why

Adicet Bio (NASDAQ:ACET) Stock Price Crosses Below 200-Day Moving Average - Time to Sell...

Ra Capital Management, L.P. Buys 74,751 Shares of Adicet Bio (NASDAQ:ACET) Stock

Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) major shareholder Ra Capital Management, L.P. purchased 74,751 shares of the business's stock in a transaction on Friday, February 20th. The shares were acquired at an average price of $7.27 per share, with a total value of $543,439.77. Following the...

Adicet Bio (NASDAQ:ACET) Major Shareholder Purchases $535,472.28 in Stock

Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) major shareholder Ra Capital Management, L.P. purchased 74,268 shares of the company's stock in a transaction on Thursday, February 19th. The shares were bought at an average price of $7.21 per share, with a total value of $535,472.28. Following the...

Adicet Bio (NASDAQ:ACET) Major Shareholder Ra Capital Management, L.P. Acquires 74,577 Shares

Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) major shareholder Ra Capital Management, L.P. bought 74,577 shares of the stock in a transaction on Wednesday, February 18th. The stock was purchased at an average price of $7.04 per share, for a total transaction of $525,022.08. Following the...

Adicet Bio (NASDAQ:ACET) Stock Price Crosses Below Two Hundred Day Moving Average - Should You Sell?

Adicet Bio (NASDAQ:ACET) Stock Passes Below 200-Day Moving Average - What's Next...

Adicet Bio, Inc. (NASDAQ:ACET) Given Average Rating of "Moderate Buy" by Analysts

Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight analysts that are covering the firm, Marketbeat reports. One analyst has...

Adicet Bio (NASDAQ:ACET) Upgraded at Truist Financial

Truist Financial upgraded Adicet Bio to a "strong-buy" rating in a research report on Wednesday...

Adicet Bio (ACET) Upgraded to Buy: Here's Why

Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Adicet Bio (NASDAQ:ACET) Price Target Cut to $27.00 by Analysts at HC Wainwright

HC Wainwright decreased their price target on Adicet Bio from $50.00 to $27.00 and set a "buy" rating on the stock in a research report on Monday...

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

ACET
Adicet Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ACET News

ACETAdicet Bio Inc